Not sure if this article has been shared here but the Gilead...

Not sure if this article has been shared here but the Gilead takeover of a biotech called Forty Seven seems to set a good benchmark of what IMU could be valued at today if the final Hervaxx results are consistent with the Interim results.

$4.9B USD has a nice ring to it...what would that be in AUD??

https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/

Gilead & Immunomedics

The AZ-Alexion deal is likely to be the only big pharma merger this year, but Gilead’s purchase of US biotech Immunomedics and its potential cancer blockbuster Trodelvy isn’t far off it in terms of value, with the deal totalling $21 billion.

California-based Gilead announced its strong intentions in oncology in 2017 with its $11.9 billion buy of Kite Pharma and followed that earlier this year by acquiring immuno-oncology firm Forty Seven for $4.9 billion (see below). Shoring up its assets in a wider range of disease areas will help the company weather the storm as the pool of patients eligible to receive its hepatitis C drugs such as Sovaldi shrinks.

Trodelvy (sacituzumab govitecan) is a first-in-class TROP2 antibody-drug conjugate drug that was granted accelerated approval by the FDA in April for adults with metastatic triple-negative breast cancer (TNBC), who have received at least two previous therapies for metastatic disease.

Data from trials of the drug wowed ESMO in September – Trodelvy was shown to significantly extend overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies.

The 500-plus patients in ASCENT had received a median of four previous anticancer treatments, but Trodelvy significantly improved OS with a median of 12.1 months, compared with 6.7 months in patients treated with chemotherapy.

Theres a PDF report from Evaluate Pharma below for anyones who would like a read.....it can also be downloaded from their website if you join.

EvaluatePharma-World-Preview-2020_0.pdf